Physician profile
Michael A Malloy
NPI 1679597371
$12,840.96
in general payments reported to CMS, 2019-2025
29 companies · $2,057 in 2025
The $2,057 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $846 · 2021: $1,401 · 2022: $2,113 · 2023: $2,537 · 2024: $2,528 · 2025: $2,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,921 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,921.33 |
| Education | $199.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,750.15 | 2019-2025 | |
| Amgen INC. | $2,554.31 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $703.68 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $678.21 | 2019-2025 | |
| Janssen Biotech, INC. | $634.57 | 2019-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $448.46 | 2019-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $409.95 | 2020-2025 | Acthar |
| Pfizer INC. | $399.39 | 2019-2025 | |
| Horizon Therapeutics Plc | $367.69 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $330.31 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $300.61 | 2019-2025 | Orencia |
| Genentech USA, INC. | $273.28 | 2019-2023 | Actemra |
| Astrazeneca Pharmaceuticals LP | $256.38 | 2023-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $152.78 | 2022-2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $124.56 | 2019-2023 | Opsumit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $102.65 | 2021-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.52 | 2020-2023 | Ofev, Cyltezo |
| Amarin Pharma, INC. | $39.21 | 2020 | |
| Collegium Pharmaceutical, INC. | $35.41 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $28.85 | 2019-2021 | |
| Sobi, INC | $26.18 | 2019 | |
| Alnylam Pharmaceuticals INC. | $25.83 | 2022 | |
| Healthtronics Stone Solutions, LLC | $24.67 | 2020 | |
| Tersera Therapeutics LLC | $18.39 | 2025 | Quzyttir |
| Genzyme Corporation | $17.02 | 2023 | |
| Alexion Pharmaceuticals, INC. | $15.67 | 2022 | |
| Mallinckrodt Enterprises LLC | $13.37 | 2019 | |
| Allergan, INC. | $11.47 | 2019 | |
| Almatica Pharma LLC | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Malloy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.